BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15279642)

  • 1. Correlation between Alcian blue-periodic acid-Schiff stain and immunohistochemical expression of mucin 2 in Barrett's oesophagus.
    Lopes CV; Pereira-Lima JC; Hartmann AA
    Histopathology; 2004 Aug; 45(2):198-9. PubMed ID: 15279642
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of mucin-2 and correlation with PAS-alcian blue stain in Barrett's esophagus.
    Lopes CV; Pereira-Lima J; Hartmann A
    Hepatogastroenterology; 2006; 53(70):511-5. PubMed ID: 16995451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CDX2 and MUC2 in Barrett's mucosa.
    Steininger H; Pfofe DA; Müller H; Haag-Sunjic G; Fratianu V
    Pathol Res Pract; 2005; 201(8-9):573-7. PubMed ID: 16259110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical mucin expression of short-segment Barrett's esophagus.
    Yamamoto S; Kijima H; Hara T; Kenmochi T; Kise Y; Tanaka H; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
    Tokai J Exp Clin Med; 2003 Jul; 28(2):57-63. PubMed ID: 14714830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
    Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
    Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastric-type mucin and TFF-peptide expression in Barrett's oesophagus is disturbed during increased expression of MUC2.
    Van De Bovenkamp JH; Korteland-Van Male AM; Warson C; Büller HA; Einerhand AW; Ectors NL; Dekker J
    Histopathology; 2003 Jun; 42(6):555-65. PubMed ID: 12786891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Morphologic and immunohistochemical aspects of Barrett esophagus].
    Lanzafame S; Fiaccavento R; Macaluso G; Canzonieri V
    Pathologica; 1987; 79(1061):313-21. PubMed ID: 3327048
    [No Abstract]   [Full Text] [Related]  

  • 8. A procedure for Alcian blue staining of mucins on polyvinylidene difluoride membranes.
    Dong W; Matsuno YK; Kameyama A
    Anal Chem; 2012 Oct; 84(20):8461-6. PubMed ID: 22950532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Fontana-Masson-mucin staining of Cryptococcus neoformans.
    Lazcano O; Speights VO; Bilbao J; Becker J; Diaz J
    Arch Pathol Lab Med; 1991 Nov; 115(11):1145-9. PubMed ID: 1720948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage.
    Amano Y; Ishihara S; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Miyake T; Miyaoka Y; Rumi MA; Ishimura N; Adachi K; Kinoshita Y
    Aliment Pharmacol Ther; 2004 Oct; 20(7):793-802. PubMed ID: 15379840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetic acid-enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus.
    Fortun PJ; Anagnostopoulos GK; Kaye P; James M; Foley S; Samuel S; Shonde A; Badreldin R; Campbell E; Hawkey CJ; Ragunath K
    Aliment Pharmacol Ther; 2006 Mar; 23(6):735-42. PubMed ID: 16556175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokeratin 7/20 immunostaining: Barrett's oesophagus or gastric intestinal metaplasia?
    Odze R
    Lancet; 2002 May; 359(9319):1711-3. PubMed ID: 12049855
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence of and risk factors for Barrett's esophagus with intestinal predominant mucin phenotype.
    Amano Y; Kushiyama Y; Yuki T; Takahashi Y; Moriyama I; Fukuhara H; Ishimura N; Furuta K; Ishihara S; Adachi K; Maruyama R; Kinoshita Y
    Scand J Gastroenterol; 2006 Aug; 41(8):873-9. PubMed ID: 16803684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
    Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
    Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mott cell (Russell bodies) Barrett's oesophagitis.
    Rubio CA
    In Vivo; 2005; 19(6):1097-100. PubMed ID: 16277029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies.
    Harrison R; Perry I; Haddadin W; McDonald S; Bryan R; Abrams K; Sampliner R; Talley NJ; Moayyedi P; Jankowski JA
    Am J Gastroenterol; 2007 Jun; 102(6):1154-61. PubMed ID: 17433019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective determination of different types of gastrointestinal mucins:use of histochemical reagents].
    Fontaine N; Meslin JC
    Reprod Nutr Dev; 1994; 34(3):237-47. PubMed ID: 7519429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined histochemical stains in the differential diagnosis of Cryptococcus neoformans.
    Lazcano O; Speights VO; Strickler JG; Bilbao JE; Becker J; Diaz J
    Mod Pathol; 1993 Jan; 6(1):80-4. PubMed ID: 7678937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer risk in Barrett's oesophagus.
    Dias Pereira A; Suspiro A; Chaves P
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Techniques and results used in staining PAS and alcian blue].
    Watanabe Y
    Rinsho Byori; 1990 Nov; Suppl 87():201-12. PubMed ID: 1704936
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.